Quinazolone RVX-208 effect on liver carcinoma cell line
Summary:
Analysis of HepG2 liver carcinoma cells treated with the quinazolone RVX-208 or the triazolothienodiazepine JQ1, a BET bromodomain (BD) inhibitor. BET protein dysfunction is linked to cancer. Results provide insight into the difference in affinity of RVX-208 for the 1st and 2nd BDs in BET proteins.
GPL6244:
[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version]
Citation:
Picaud S, Wells C, Felletar I, Brotherton D et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A 2013 Dec 3;110(49):19754-9. PMID: 24248379
